ASCO-GU – Keytruda strengthens its kidney cancer monopoly
Merck adds an overall survival benefit while Bristol sinks further.
KRAS crowding continues
Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T.
ESMO 2023 – not so fast, Welireg
The Merck & Co drug's first successful phase 3 study might not be all it’s cracked up to be.
